Short answer
TuHURA Biosciences, Inc./NV (HURA) filed its Q1 2026 10-Q quarterly report on May 15, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $0 with net income of −$8M.
Q1 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$8M
- −13.1% YoY
- EPS (diluted)
- −$0.13
- +13.3% YoY
Source: XBRL data from the TuHURA Biosciences, Inc./NV (HURA) Q1 2026 10-Q on SEC EDGAR. USD.
TuHURA Biosciences, Inc./NV Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly triggered financing risk: $50 million Parkview facility carries 12% interest and security over substantially all company assets
- Most materially updated liquidity risk: $6.3 million cash at March 31, 2026, with $4.4 million quarterly operating cash burn
- Clinical development risk: Phase 3 IFx-2.0 trial and planned Phase 2 TBS-2025 trial increase unpredictable enrollment, cost, and regulatory-approval uncertainty
- Financial dilution risk: ATM Program permits up to $50 million of common-stock sales
- Commercial risk: No approved products or product revenue, requiring substantial additional funding through potential profitability date
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TuHURA Biosciences, Inc./NV quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.